Waiting for the next wave...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Created a stock screener showing the OTC stocks that have a positive P/E ratio.
Not Many companies out there that are in the list:
8 Screen Results
8 Screen Results
Click to sort bySymbol Click to sort byDescription Click to sort bySector Click to sort byIndustry Click to sort bySub-Industry Click to sort byExchange Click to sort byPrice/ Earnings (TTM)
DSNKY
Daiichi Sankyo Co Ltd Health Care Pharmaceuticals Pharmaceuticals OTC 50.31 Click to launch a chart and summary for Daiichi Sankyo Co Ltd in a new window
EDXC
Endexx Corp Health Care Pharmaceuticals Pharmaceuticals OTC 1.81 Click to launch a chart and summary for Endexx Corp in a new window
ELTP
Elite Pharmaceuticals Inc Health Care Pharmaceuticals Pharmaceuticals OTC 8.65 Click to launch a chart and summary for Elite Pharmaceuticals Inc in a new window
ENZN
Enzon Pharmaceuticals Inc Health Care Biotechnology Biotechnology OTC 64.39 Click to launch a chart and summary for Enzon Pharmaceuticals Inc in a new window
LADX
LadRx Corp Health Care Biotechnology Biotechnology OTC 5.12 Click to launch a chart and summary for LadRx Corp in a new window
MDRX
Veradigm Inc Health Care Health Care Technology Health Care Technology OTC 8.09 Click to launch a chart and summary for Veradigm Inc in a new window
MKKGY
Merck KGaA Health Care Pharmaceuticals Pharmaceuticals OTC 23.68 Click to launch a chart and summary for Merck KGaA in a new window
RHHBY
Roche Holding AG Health Care Pharmaceuticals Pharmaceuticals OTC 15.45 Click to launch a chart and summary for Roche Holding AG in a new window
The old wolf has contacts Not worried he will deliver.
Polaroid !!! Rhymes with Hemo....
This is a list of stocks I got from the web - OTC stocks are not on it.
I wanted to see how high PE ratio could go - and there was one over 7000 - totally shortable
Agree - one stock has a PE ratio over 7000 lol
I could live with that
8395 companies by P/E ratio
https://companiesmarketcap.com/top-companies-by-pe-ratio/
What is a good P/E ratio?
companies: 8,386 average P/E ratio (TTM): 14.5 The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued.
If history of a stock had so much impact on the future of a stock, there would be no investor .
Cut the BS...
I think we are the ONLY stock making money on the OTC lol
----------------
Is there a lower PE on the OTC exchange ??
Goatlanders and Longs have the same goal - Buyout !!!! They just have deeper pockets and want it to stay low for as long as possible...
BBQ !!!! Kebab !!!
About 37 trading days to Teleconference - a lot can happen with ANDA's
Sitting on a Canon Powder barrel LOL
I have no internal knowledge.
It is just that it has been a while since we got news.
We should hear about anda approvals any day.
That’s why they call them ANDA’s. lol.
Answer to the riddle:
People who are paid to do the work of others interested in manipulating a stock to keep it as low as possible patiently until there is a buy out of the company and a huge cash out.
FFTC
Do you have 550K shares?
I think News day is Wednesday
Soooo cheap
500K shares mid day - definitely waking up...
No - it is clearly showing that their apps are getting the data from different databases.
This is what happens when you do a hack after purchasing other trading platforms.
There should be 1 and only 1 source of truth.
They fixed it - But they are not reliable.
This is crazy - after 8:30 AM I see a 25K difference on my totals between the two apps...
Schwab is scr***d up - different totals on their 2 apps - thinkorswim and web app. Also all the gains from yesterday disappeared
We need more bold!!!
Nice close !!!
It wasn't me
Come on - we are short 8 cents from where we were at the top
We can do it
I disagree with that theory.
We will see a raise in pps as we get closer to the conference date. To 18-20 cents levels
Then if we have good results we could change digit.
Right now we do not have large institutions that maintain our price at the right level - WE, the BIG LONGS are playing that role but we do not have the deep pockets of the institutions - as soon as we move to NASDAQ, Goatland should disappear from the horizon...
Mikah will NEVER buy Elite - the question shows how little you understand of what is going on with this company, OR you are just playing Dumb to make 10 cents for a reply.
Mikah IS Nasrat Hakim - Nasrat Hakim will not take money from his right pocket to put it in his left pocket.
Mikah will be bought by Pfizer or Merck or another big pharma. and the price will START at $3.5 and may go up to $5.
at $.52 I would retire on the spot - and keep at least half of my Eltp investment (to secure my retirement).
Schwab Users - soon T+1
https://www.schwab.com/learn/story/7-things-to-know-about-t1-settlement
Much higher volatility
You woke them up
Hi Longs, (I have muted all the goatlanders) let's start early discussing the next quarter numbers - this is not yet the posting of your estimates - but more the potential catalysts that will impact the numbers that you will post two weeks before the teleconference
I say -
1. Prasco may surprise us.
2. Adderall drought in pharmacies may play in our favor
3. Kirko Kirkov may have cooked something nice for us
4. feel free to add ...
Cheers
He never bought any.
Interested in PPS (unlike you), because I may be able to accelerate my retirement date.
Are all you guys in Vegas and did not tell me to come over? LOL
Wake up
the answer to Pharma Sleuth famous question: Do you know why you are here?
Financial Times article from March 26th 2024
Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour.
https://www.ft.com/content/4fe0f032-07e5-41d7-ac85-cceb252129a3
File under: huge if true. A group of Wall Street traders maliciously drove down the share price of a Maryland biotech with a promising new brain cancer vaccine, in pursuit of the marginal profits to be made by buying the stock cheaply and selling it back to the market.
That, at least, was the allegation made by Northwest Biotherapeutics in a suit filed against seven broker-dealers including Virtu and Ken Griffin’s Citadel Securities in late 2022.
It accused the firms of “repeated spoofing” by using their trading platforms to place tens of millions of orders to sell NWBO that they had no intention of fulfilling. These orders were visible to the rest of the market, the complaint alleged, which led other investors to dump the shares, hammering NWBO’s valuation even as a key clinical trial yielded impressive results.
Predictably, the claims sent conspiracy-minded Redditors — including some of those who previously pumped meme stocks such as Gamestop — into a frenzy. Their refrain for several months has been that hedge funds “want to bury this company”, while largely avoiding mention of factors that might have dissuaded investors from buying into NWBO, such as a study questioning the design of its cancer trial and a negative news report on its results. Northwest had also been mired in governance problems, settling with the SEC over failures in financial reporting oversight.
Last month, NWBO and its Reddit fans were rebuffed by a Manhattan court, which granted Citadel et al’s motion to dismiss the case.
But there was a sting in the tail. In his report recommending dismissal, magistrate Gary Stein concluded that while the company had not yet done enough to tie the trading in question to losses sustained by selling shares at the artificially low prices on specific dates, almost all of NWBO’s other claims were prima facie plausible enough to be allowed to proceed.
An attempted distinction by Citadel Securities and others between orders that were cancelled or merely reduced in volume was “unconvincing”, Stein wrote. He also concluded that at this stage in the litigation, it mattered not whether they were executing orders on behalf of clients, as they exerted “control over the high-speed trading algorithms” behind the trades.
He further found that when “viewed in the light most favourable” to the plaintiff, the “allegations amply support the inference that defendants’ conduct affected the market price for NWBO stock”. In a line that seemed destined to make its way on to the r/wallstreetbets message boards on Reddit, Stein further called the claims “cogent and at least as compelling as the inference that defendants were simply engaged in legitimate trading activity.”
The report came hot on the heels of another spoofing decision in the same New York courthouse, in a civil case brought by Bermudian hedge fund Harrington against Bank of America Merrill Lynch, CIBC and TD Securities. That suit — which was referenced by Stein — survived a motion to dismiss and is currently scheduled to go to trial as early as this year.
NWBO intends to refile its complaint within days. This time around, if a judge finds the deficiencies in the biotech’s case have been fixed, it could pave the way for the so-called discovery process in which Citadel Securities and its co-defendants would be compelled to hand over internal records and relevant communications. Critics of high-frequency trading firms, who claim they have an outsized and malign influence on global markets, will be watching closely.
Citadel Securities labelled the case a “malicious lawsuit [that] blatantly misrepresents how the market functions in an attempt to shake down the world’s leading liquidity providers”, and neither Northwest nor Harrington is necessarily any closer to proving their claims. To date, no spoofing case outside those brought by the US prosecutors or regulators has prevailed.
But the default stance adopted by market-makers — who claim allegations of market manipulation are implausible while declining to divulge the commercially sensitive intricacies of their high-tech platforms — has now been effectively knocked back.
Recommended
News in-depthUnhedged podcast
Inside the traders’ black box
Stein wrote that the fact NWBO did not specify what algorithmic trading programmes were used by defendants to execute their schemes or how they were used was not an impediment to its case. “It is hard to imagine how any spoofing case would survive the motion to dismiss stage if?.?.?.?‘facts solely within the defendant’s knowledge,’ were required to be set forth in the complaint”, he added. In other words, if Citadel Securities and its ilk are to beat this case and prevent a string of copycat suits, they will probably have to give the rest of us more of a peek behind the curtain.
joe.miller@ft.com
@ELTP Emperor - your goatland connection seems to f up.
I am sure yours is bigger
You are asking a lot.
It looks like if the dummy listened to you